期刊
INTERNATIONAL JOURNAL OF CANCER
卷 139, 期 3, 页码 501-509出版社
WILEY
DOI: 10.1002/ijc.30051
关键词
arginine deprivation; recombinant human arginase; arginine deiminase
类别
资金
- MRC [MC_PC_14123] Funding Source: UKRI
- Medical Research Council [MC_PC_14123] Funding Source: Medline
- Cancer Research UK [22590, 17973] Funding Source: researchfish
Renewed interest in the use of therapeutic enzymes combined with an improved knowledge of cancer cell metabolism, has led to the translation of several arginine depletion strategies into early phase clinical trials. Arginine auxotrophic tumors are reliant on extracellular arginine, due to the downregulation of arginosuccinate synthetase or ornithine transcarbamylase-key enzymes for intracellular arginine recycling. Engineered arginine catabolic enzymes such as recombinant human arginase (rhArg1- PEG) and arginine deiminase (ADI-PEG) have demonstrated cytotoxicity against arginine auxotrophic tumors. In this review, we discuss the molecular events triggered by extracellular arginine depletion that contribute to tumor cell death.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据